RA
BIIB icon

Rise Advisors’s Biogen BIIB Stock Holding History

Rise Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-166
Closed -$23.3K – 257
2025
Q3 		$23.3K Buy
166
+18
+12% +$2.43K 0.01% 498
2025
Q2 		$18.6K Hold
148
– – 0.01% 580
2025
Q1 		$20.3K Buy
148
+22
+17% +$3.15K 0.01% 493
2024
Q4 		$19.3K Hold
126
– – 0.01% 686
2024
Q3 		$24.4K Hold
126
– – 0.01% 549
2024
Q2 		$29.2K Hold
126
– – 0.02% 396
2024
Q1 		$27.2K Buy
+126
New +$29.5K 0.01% 437

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rise Advisors's BIIB Position: Q4 2025 in Review

Rise Advisors sold out of Biogen (BIIB) in Q4 2025, closing a stake of 166 shares — an estimated $23.3K sold.

Rise Advisors first reported a position in BIIB in Q1 2024 and held it in 7 quarters. The position peaked at $29.2K in Q2 2024. 1,000 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

  • Rise Advisors reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 166 Biogen shares in Q4 2025, an estimated $23.3K.
  • Rise Advisors first reported a position in Biogen in Q1 2024 and held it in 7 quarters.
  • Rise Advisors's Biogen position peaked at $29.2K in Q2 2024.
  • 1,000 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.